Results 1 to 10 of about 115,987 (377)

Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease

Frontiers in Immunology, 2023
Neutrophils have a critical role in the innate immune response to infection and the control of inflammation. A key component of this process is the release of neutrophil serine proteases (NSPs), primarily neutrophil elastase, proteinase 3, cathepsin G ...
James D. Chalmers, Ralph Kettritz, Ralph Kettritz, Brice Korkmaz   +3 more
doaj   +2 more sources

Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation [PDF]

Acta Dermato-Venereologica
Psoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus.
Chih-Tsung Hung, Chi-Hsiang Chung, Tsu-Hsuan Weng, Chun-Teng Tsai, Wu-Chien Chien, Yung-Lung Chang   +5 more
doaj   +2 more sources

Dipeptidyl peptidase-1 inhibitors in bronchiectasis [PDF]

European Respiratory Review
Dipeptidyl peptidase (DPP)-1 (also known as cathepsin C) inhibitors are the first disease-specific therapy shown to be effective in bronchiectasis. The mechanism of action of DPP-1 inhibitors is suppression of activity of neutrophil serine proteases ...
Emma Johnson, Amy Gilmour, James D. Chalmers   +2 more
doaj   +2 more sources

Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress. [PDF]

FASEB J
Zhang M, Wang H, Li X, Shu S, Piao J, Yue X, Zhao S, Li M, Jin X, Nan Y, Cheng XW.   +10 more
europepmc   +3 more sources

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]

, 2014
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen, AA Riedel, AI Adler, AJ Garber, AR Saltiel, BD Green, BI Yan, BM Scirica, Brian C. Y. Fong, C Castell, C Levetan, Carmen K. M. Fan, CC Cowie, CE Van Dijk, CJ Bailey, CN Chan, Daisy D. X. Zhang, DC Simonson, DR Owens, DS Schade, FA Guisasola, François Blachier, Harry H. X. Wang, J Lopatynski, J Mest H, J Rosenstock, K Kaku, Kirin Q. L. Liu, L Groop, M Kobayashi, M Stumvoll, M Takihata, Mandy W. M. Kwan, Martin C. S. Wong, MC Wong, N Inagaki, N Inagaki, O Mosenzon, R Kawamori, RA DeFronzo, S Aronoff, S Clement, SE Kahn, SE Kahn, SE Nissen, Shannon T. S. Li, Sian M. Griffiths, Sky W. M. Chan, SL Zhang, T Kadowaki, V Mohan, W Gareth, W Yang, WB White, Y Guan, Y Seino, Y Seino, YG Kim, Z Zeng   +58 more
core   +13 more sources

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. [PDF]

PLoS ONE, 2016
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12 ...
Charles E Grimshaw, Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, Takuo Kosaka, Akiyoshi Tani, Hiroki Sano, Yoshinobu Kinugawa, Emiko Koumura, Lihong Shi, Koji Takeuchi   +11 more
doaj   +1 more source

Evolutionary Analysis of Dipeptidyl Peptidase I [PDF]

International Journal of Molecular Sciences, 2022
Human dipeptidyl peptidase I (DPPI) belongs to the family of papain-like cysteine peptidases. Its distinctive features are the unique exclusion domain which enables the eponymous activity and homotetramerization of DPPI, and its dependence on chloride ions for enzymatic activity.
Nina Varda, Marko Novinec
openaire   +3 more sources

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors

Endocrinology, Diabetes & Metabolism, 2021
Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna, Skotnikova Kseniia Petrovna, Vtorushina Anna Anatolievna, Uskov Ivan Sergeyevich, Rogoza Olga Vladimirovna, Grozov Roman Viktorovich, Babenko Alina Yurievna, Galagudza Mikhail Mikhailovich   +7 more
doaj   +1 more source

Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial [PDF]

, 2020
Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Brighton, Paul (Paul J.), Brosens, Jan J., Da Costa, Maria José Minhoto Diniz, Ewington, Lauren J., Fishwick, Katherine, Fujihara, Risa, Kimani, Peter K., Lacey, Lauren, Lucas, Emma S., Muter, Joanne, Polanco, Angela, Quenby, Siobhan, Takeda, Satoru, Tewary, Shreeya   +13 more
core   +1 more source

SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19

Metabolism Open, 2021
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two ...
Zemene Demelash Kifle, Alem Endeshaw Woldeyohanin, Chilot Abiyu Demeke   +2 more
doaj   +1 more source